Literature DB >> 2119843

Differential effects of petit mal anticonvulsants and convulsants on thalamic neurones: GABA current blockade.

D A Coulter1, J R Huguenard, D A Prince.   

Abstract

1. Currents evoked by applications of gamma-aminobutyric acid (GABA) to acutely dissociated thalamic neurones were analysed by voltage-clamp techniques, and the effects of the anticonvulsant succinimides ethosuximide (ES) and alpha-methyl-alpha-phenylsuccinimide (MPS) and the convulsants tetramethylsuccinimide (TMS), picrotoxin, pentylenetetrazol (PTZ), and bicuculline methiodide were assessed. 2. TMS (1 microM-10 microM) reduced responses to iontophoretically applied GABA, as did picrotoxin (0.1-100 microM), PTZ (1-100 mM) and bicuculline (1-100 microM). 3. ES, in high concentrations (1-10 mM), reduced GABA responses to a lesser extent, and also occluded the reductions in GABA-evoked currents produced by TMS, picrotoxin, and PTZ. ES did not occlude the effects of bicuculline on GABA responses. Therefore, we propose that ES acts as a partial agonist at the picrotoxin GABA-blocking receptor. 4. MPS had no effect on GABA responses (at a concentration of 1 mM), and, like ES, occluded the GABA-blocking actions of TMS, apparently acting as a full antagonist. 5. The anticonvulsant actions of ES and MPS against TMS and PTZ-induced seizures may thus involve two independent mechanisms: (1) the occlusion of TMS and PTZ GABA-blocking effects; and (2) the previously described specific effect of ES and MPS on low-threshold calcium current of thalamic neurones. The latter cellular mechanism may be more closely related to petit mal anticonvulsant activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2119843      PMCID: PMC1917578          DOI: 10.1111/j.1476-5381.1990.tb14096.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

1.  Pentylenetetrazol and penicillin are selective antagonists of GABA-mediated post-synaptic inhibition in cultured mammalian neurones.

Authors:  R L Macdonald; J L Barker
Journal:  Nature       Date:  1977-06-23       Impact factor: 49.962

Review 2.  Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations.

Authors:  W Löscher; D Schmidt
Journal:  Epilepsy Res       Date:  1988 May-Jun       Impact factor: 3.045

Review 3.  Drug interactions at the GABA receptor-ionophore complex.

Authors:  R W Olsen
Journal:  Annu Rev Pharmacol Toxicol       Date:  1982       Impact factor: 13.820

4.  Classification of some GABA antagonists with regard to site of action and potency in slices of rat cuneate nucleus.

Authors:  M A Simmonds
Journal:  Eur J Pharmacol       Date:  1982-06-04       Impact factor: 4.432

5.  [35S]t-butylbicyclophosphorothionate binds with high affinity to brain-specific sites coupled to gamma-aminobutyric acid-A and ion recognition sites.

Authors:  R F Squires; J E Casida; M Richardson; E Saederup
Journal:  Mol Pharmacol       Date:  1983-03       Impact factor: 4.436

6.  Evidence that bicuculline and picrotoxin act at separate sites to antagonize gamma-aminobutyric acid in rat cuneate nucleus.

Authors:  M A Simmonds
Journal:  Neuropharmacology       Date:  1980-01       Impact factor: 5.250

7.  Comparison of epileptogenic properties of unsubstituted and beta-alkyl-substituted gamma-butyrolactones.

Authors:  W E Klunk; D F Covey; J A Ferrendelli
Journal:  Mol Pharmacol       Date:  1982-09       Impact factor: 4.436

8.  Structure-activity relationships of alkyl-substituted gamma-butyrolactones and succinimides.

Authors:  W E Klunk; D F Covey; J A Ferrendelli
Journal:  Mol Pharmacol       Date:  1982-09       Impact factor: 4.436

9.  Ethosuximide in the treatment of absence (peptit mal) seizures.

Authors:  T R Browne; F E Dreifuss; P R Dyken; D J Goode; J K Penry; R J Porter; B G White; P T White
Journal:  Neurology       Date:  1975-06       Impact factor: 9.910

10.  Anticonvulsant properties of alpha, gamma, and alpha, gamma-substituted gamma-butyrolactones.

Authors:  W E Klunk; D F Covey; J A Ferrendelli
Journal:  Mol Pharmacol       Date:  1982-09       Impact factor: 4.436

View more
  8 in total

1.  Rapid seizure-induced reduction of benzodiazepine and Zn2+ sensitivity of hippocampal dentate granule cell GABAA receptors.

Authors:  J Kapur; R L Macdonald
Journal:  J Neurosci       Date:  1997-10-01       Impact factor: 6.167

2.  Differential effects of petit mal anticonvulsants and convulsants on thalamic neurones: calcium current reduction.

Authors:  D A Coulter; J R Huguenard; D A Prince
Journal:  Br J Pharmacol       Date:  1990-08       Impact factor: 8.739

3.  Potent analgesic effects of anticonvulsants on peripheral thermal nociception in rats.

Authors:  Slobodan M Todorovic; A J Rastogi; Vesna Jevtovic-Todorovic
Journal:  Br J Pharmacol       Date:  2003-08-04       Impact factor: 8.739

4.  Experimental status epilepticus alters gamma-aminobutyric acid type A receptor function in CA1 pyramidal neurons.

Authors:  J Kapur; D A Coulter
Journal:  Ann Neurol       Date:  1995-12       Impact factor: 10.422

Review 5.  T-type Ca2+ channels in absence epilepsy.

Authors:  Eunji Cheong; Hee-Sup Shin
Journal:  Pflugers Arch       Date:  2014-02-13       Impact factor: 3.657

Review 6.  Strategies for identifying and developing new anticonvulsant drugs.

Authors:  H J Kupferberg
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

7.  RDX binds to the GABA(A) receptor-convulsant site and blocks GABA(A) receptor-mediated currents in the amygdala: a mechanism for RDX-induced seizures.

Authors:  Larry R Williams; Vassiliki Aroniadou-Anderjaska; Felicia Qashu; Huckelberry Finne; Volodymyr Pidoplichko; Desmond I Bannon; Maria F M Braga
Journal:  Environ Health Perspect       Date:  2011-03       Impact factor: 9.031

8.  Targeting Neural Synchrony Deficits is Sufficient to Improve Cognition in a Schizophrenia-Related Neurodevelopmental Model.

Authors:  Heekyung Lee; Dino Dvorak; André A Fenton
Journal:  Front Psychiatry       Date:  2014-02-14       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.